Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 16.

Schandelmaier, S; Conen, K; von Elm, E; You, J J; Blümle, A; Tomonaga, Yuki; Saccilotto, R; Amstutz, A; Bengough, T; Meerpohl, J J; Stegert, M; Olu, K K; Tikkinen, K A O; Neumann, I; Carrasco-Labra, A; Faulhaber, M; Mulla, S M; Mertz, D; Akl, E A; Sun, X; Bassler, D; Busse, J W; Ferreira-González, I; Lamontagne, F; Nordmann, A; Gloy, V; Raatz, H; Moja, L; Rosenthal, R; Ebrahim, S; Vandvik, P O; Johnston, B C; Walter, M A; Burnand, B; Schwenkglenks, Matthias; Hemkens, L G; Bucher, H C; Guyatt, G H; Briel, M; Kasenda, B; DISCO Study Group (2016). Planning and reporting of quality-of-life outcomes in cancer trials. Annals of Oncology, 27(1):209.

Schäfer, J; Young, J; Bernasconi, E; Ledergerber, B; Nicca, D; Calmy, A; Cavassini, M; Furrer, H; Battegay, M; Bucher, H C; Swiss HIV Cohort Study (2015). Predicting smoking cessation and its relapse in HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 16(1):3-14.

Young, J; Wang, Q; Fux, C A; Bernasconi, E; Furrer, H; Vernazza, P; Calmy, A; Cavassini, M; Weber, R; Battegay, M; Bucher, H C (2014). The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir. HIV Medicine, 15(8):505-510.

Schöni-Affolter, F; Keiser, O; Mwango, A; Stringer, J; Ledergerber, B; Mulenga, L; Bucher, H C; Westfall, A O; Calmy, A; Boulle, A; Chintu, N; Egger, M; Chi, B H (2011). Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: The effect of the competing risk of death in Zambia and Switzerland. PLoS ONE, 6(12):e27919.

Magenta, L; Dell-Kuster, S; Richter, W O; Young, J; Hasse, B; Flepp, M; Hirschel, B; Vernazza, P; Evison, J; Cavassini, M; Decosterd, L A; Bucher, H C; Bernasconi, E (2011). Lipid and lipoprotein profile in HIV-infected patients treated with Lopinavir/Ritonavir as a component of the first combination antiretroviral therapy. AIDS Research and Human Retroviruses, 27(5):525-533.

Fehr, J; Glass, T R; Louvel, S; Hamy, F; Hirsch, H H; von Wyl, V; Böni, J; Yerly, S; Bürgisser, P; Cavassini, M; Fux, C A; Hirschel, B; Vernazza, P; Martinetti, G; Bernasconi, E; Günthard, H F; Battegay, M; Bucher, H C; Klimkait, T (2011). Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study. Journal of Translational Medicine, 9:14.

Cain, L E; Logan, R; Robins, J M; Sterne, J A C; Sabin, C; Bansi, L; Justice, A; Goulet, J; van Sighem, A; de Wolf, F; Bucher, H C; von Wyl, V; Esteve, A; Casabona, J; del Amo, J; Moreno, S; Seng, R; Meyer, L; Perez-Hoyos, S; Muga, R; Lodi, S; Lanoy, E; Costagliola, D; Hernan, M A (2011). When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Annals of Internal Medicine, 154(8):509-515.

Glass, T R; Battegay, M; Cavassini, M; De Geest, S; Furrer, H; Vernazza, P L; Hirschel, B; Bernasconi, E; Rickenbach, M; Günthard, H F; Bucher, H C (2010). Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. JAIDS Journal of Acquired Immune Deficiency Syndromes, 54(2):197-203.

Scherrer, A U; von Wyl, V; Fux, C A; Opravil, M; Bucher, H C; Fayet, A; Decosterd, L A; Hirschel, B; Khanlari, B; Yerly, S; Klimkait, T; Furrer, H; Ledergerber, B; Günthard, H F (2010). Implementation of Raltegravir in routine clinical practice: Selection criteria for choosing this drug, virologic response rates, and characteristics of failures. JAIDS Journal of Acquired Immune Deficiency Syndromes, 53(4):464-471.

Rudin, C; Wolbers, M; Nadal, D; Rickenbach, M; Bucher, H C (2010). Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children. Archives of Disease in Childhood, 95(6):478-481.

Bucher, H C; Rickenbach, M; Young, J; Glass, T R; Vallet, Y; Bernasconi, E; Cavassini, M; Fux, C; Schiffer, V; Vernazza, P; Weber, R; Battegay, M (2010). Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy. Antiviral Therapy, 15(1):31-40.

Scherrer, A U; Hasse, B; von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Bucher, H C; Ledergerber, B; Günthard, H F (2009). Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). HIV Medicine, 10(10):647-656.

Conen, A; Fehr, J; Glass, T R; Furrer, H; Weber, R; Vernazza, P; Hirschel, B; Cavassini, M; Bernasconi, E; Bucher, H C; Battegay, M (2009). Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. Antiviral Therapy, 14(3):349-357.

Young, J; Bucher, H C; Guenthard, H F; Rickenbach, M; Fux, C A; Hirschel, B; Cavassini, M; Vernazza, P; Bernasconi, E; Battegay, M (2009). Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. Antiviral Therapy, 14(6):771-779.

Wolbers, M; Bucher, H C; Furrer, H; Rickenbach, M; Cavassini, M; Weber, R; Schmid, P; Bernasconi, E; Hirschel, B; Battegay, M (2008). Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Medicine, 9(6):397-405.

Glass, T R; De Geest, S; Hirschel, B; Battegay, M; Furrer, H; Covassini, M; Vernazza, P L; Bernasconi, E; Rickenboch, M; Weber, R; Bucher, H C; Swiss HIV Cohort Study (2008). Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antiviral Therapy, 13(1):77-85.

This list was generated on Sat Nov 25 12:59:19 2017 CET.